<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38231284</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1591-9528</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>17</Day></PubDate></JournalIssue><Title>Clinical and experimental medicine</Title><ISOAbbreviation>Clin Exp Med</ISOAbbreviation></Journal><ArticleTitle>The demographic, laboratory and genetic factors associated with long Covid-19 syndrome: a case-control study.</ArticleTitle><Pagination><StartPage>1</StartPage><MedlinePgn>1</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10238-023-01256-1</ELocationID><Abstract><AbstractText>Long Covid-19 syndrome (LCS) manifests with a wide range of clinical symptoms, yet the factors associated with LCS remain poorly understood. The current study aimed to investigate the relationships that demographic characteristics, clinical history, laboratory indicators, and the frequency of HLA-I alleles have with the likelihood of developing LCS. We extracted the demographic characteristics and clinical histories from the medical records of 88 LCS cases (LCS<sup>+</sup> group) and 96 individuals without LCS (LCS<sup>-</sup> group). Furthermore, we evaluated the clinical symptoms, serum levels of interleukin (IL)-6 and tumor necrosis factor-&#x3b1;, laboratory parameters, and the frequencies of HLA-I alleles. Following this we used multiple logistic regression to investigate the association these variables had with LCS. Subjects in the LCS<sup>+</sup> group were more likely to have experienced severe Covid-19 symptoms and had higher body mass index (BMI), white blood cell, lymphocyte counts, C-reactive protein (CRP), and IL-6 levels than those in the LCS<sup>-</sup> group (for all: P&#x2009;&lt;&#x2009;0.05). Moreover, the frequencies of the HLA-A*11, -B*14, -B*38, -B*50, and -C*07 alleles were higher in the LCS<sup>+</sup> group (for all: P&#x2009;&lt;&#x2009;0.05). After adjusting for the most important variables, the likelihood of suffering from LCS was significantly associated with BMI, CRP, IL-6, the HLA-A*11, and -C*07 alleles, as well as a positive history of severe Covid-19 (for all: P&#x2009;&lt;&#x2009;0.05). Our study showed that a history of severe Covid-19 during the acute phase of the disease, the HLA-A*11, and -C*07 alleles, higher BMI, as well as elevated serum CRP and IL-6 levels, were all associated with an increased likelihood of LCS.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Torki</LastName><ForeName>Ensiye</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoseininasab</LastName><ForeName>Fahimeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moradi</LastName><ForeName>Marjan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genetics, School of Science, Shahrekord University, Shahrekord, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sami</LastName><ForeName>Ramin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullman</LastName><ForeName>Mark J M</ForeName><Initials>MJM</Initials><AffiliationInfo><Affiliation>Department of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Social Sciences, University of Nicosia, Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fouladseresht</LastName><ForeName>Hamed</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. fouladseresht@med.mui.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>3400839</GrantID><Agency>Isfahan University of Medical Sciences</Agency><Country/></Grant><Grant><GrantID>3400839</GrantID><Agency>Isfahan University of Medical Sciences</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Exp Med</MedlineTA><NlmUniqueID>100973405</NlmUniqueID><ISSNLinking>1591-8890</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015234">HLA-A Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015234" MajorTopicYN="N">HLA-A Antigens</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HLA class I</Keyword><Keyword MajorTopicYN="N">Interleukin-6</Keyword><Keyword MajorTopicYN="N">Long Covid-19 syndrome</Keyword><Keyword MajorTopicYN="N">Severity</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>17</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>17</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38231284</ArticleId><ArticleId IdType="pmc">PMC10794331</ArticleId><ArticleId IdType="doi">10.1007/s10238-023-01256-1</ArticleId><ArticleId IdType="pii">10.1007/s10238-023-01256-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Castanares-Zapatero D, Chalon P, Kohn L, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54:1473&#x2013;1487. doi: 10.1080/07853890.2022.2076901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2076901</ArticleId><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Perumal R, Shunmugam L, Naidoo K, et al. Long COVID: a review and proposed visualization of the complexity of long COVID. Front Immunol. 2023;14:1117464. doi: 10.3389/fimmu.2023.1117464.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1117464</ArticleId><ArticleId IdType="pmc">PMC10157068</ArticleId><ArticleId IdType="pubmed">37153597</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102&#x2013;7. doi: 10.1016/s1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226:1593&#x2013;607. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond.) 2021;53:737&#x2013;54. doi: 10.1080/23744235.2021.1924397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Mccorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2013;46. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Julg B, Mohandas S, Bradfute SB. Viral persistence, reactivation, and mechanisms of long COVID. Elife. 2023;12:e86015. doi: 10.7554/eLife.86015.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86015</ArticleId><ArticleId IdType="pmc">PMC10159620</ArticleId><ArticleId IdType="pubmed">37140960</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JJL. Persistent SARS-2 infections contribute to long COVID-19. Med Hypotheses. 2021;149:110538. doi: 10.1016/j.mehy.2021.110538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2021.110538</ArticleId><ArticleId IdType="pmc">PMC7884250</ArticleId><ArticleId IdType="pubmed">33621843</ArticleId></ArticleIdList></Reference><Reference><Citation>The L. Understanding long COVID: a modern medical challenge. Lancet. 2021;398:725. doi: 10.1016/s0140-6736(21)01900-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)01900-0</ArticleId><ArticleId IdType="pmc">PMC8389978</ArticleId><ArticleId IdType="pubmed">34454656</ArticleId></ArticleIdList></Reference><Reference><Citation>Koc HC, Xiao J, Liu W, Li Y, Chen G. Long COVID and its management. Int J Biol Sci. 2022;18:4768&#x2013;4780. doi: 10.7150/ijbs.75056.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.75056</ArticleId><ArticleId IdType="pmc">PMC9305273</ArticleId><ArticleId IdType="pubmed">35874958</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, De Oliveira MHS, Peligro PJ, et al. Age, sex and previous comorbidities as risk factors not associated with SARS-CoV-2 infection for long COVID-19: a systematic review and meta-analysis. J Clin Med. 2022;11:7314. doi: 10.3390/jcm11247314.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11247314</ArticleId><ArticleId IdType="pmc">PMC9787827</ArticleId><ArticleId IdType="pubmed">36555931</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. E Clin Med. 2022;53:101624. doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-De-Las-Pe&#xf1;as C, Notarte KI, Peligro PJ, et al. Long-COVID symptoms in individuals infected with different SARS-CoV-2 variants of concern: a systematic review of the literature. Viruses. 2022;14:2629. doi: 10.3390/v14122629.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122629</ArticleId><ArticleId IdType="pmc">PMC9785120</ArticleId><ArticleId IdType="pubmed">36560633</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackwell JM, Jamieson SE, Burgner D. HLA and infectious diseases. Clin Microbiol Rev. 2009;22:370&#x2013;85. doi: 10.1128/cmr.00048-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/cmr.00048-08</ArticleId><ArticleId IdType="pmc">PMC2668228</ArticleId><ArticleId IdType="pubmed">19366919</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosaad YM. Clinical role of human leukocyte antigen in health and disease. Scand J Immunol. 2015;82:283&#x2013;306. doi: 10.1111/sji.12329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12329</ArticleId><ArticleId IdType="pubmed">26099424</ArticleId></ArticleIdList></Reference><Reference><Citation>Medhasi S, Chantratita N. Human leukocyte antigen (HLA) system: genetics and association with bacterial and viral infections. J Immunol Res. 2022;2022:9710376. doi: 10.1155/2022/9710376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/9710376</ArticleId><ArticleId IdType="pmc">PMC9162874</ArticleId><ArticleId IdType="pubmed">35664353</ArticleId></ArticleIdList></Reference><Reference><Citation>Augusto DG, Hollenbach JA. HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection. Curr Opin Immunol. 2022;76:102178. doi: 10.1016/j.coi.2022.102178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2022.102178</ArticleId><ArticleId IdType="pmc">PMC8947957</ArticleId><ArticleId IdType="pubmed">35462277</ArticleId></ArticleIdList></Reference><Reference><Citation>Krensky AM. The HLA system, antigen processing and presentation. Kidney Int Suppl. 1997;58:S2&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9067934</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell WM. HLA and disease: guilt by association. Int J Immunogenet. 2014;41:1&#x2013;12. doi: 10.1111/iji.12088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iji.12088</ArticleId><ArticleId IdType="pubmed">24004450</ArticleId></ArticleIdList></Reference><Reference><Citation>Li WX, Xia JA, Zhou X, Ma Y, Shen G, Qiu FW. Association of HLA alleles (A, B, DRB1) and HIV-1 infection in the Han population of Hubei, China. J Huazhong Univ Sci Technolog Med Sci. 2017;37:131&#x2013;139. doi: 10.1007/s11596-017-1706-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11596-017-1706-z</ArticleId><ArticleId IdType="pubmed">28224433</ArticleId></ArticleIdList></Reference><Reference><Citation>Meysman P, Ogunjimi B, Naulaerts S, Beutels P, Van Tendeloo V, Laukens K. Varicella-zoster virus-derived major histocompatibility complex class I-restricted peptide affinity is a determining factor in the HLA risk profile for the development of postherpetic neuralgia. J Virol. 2015;89:962&#x2013;969. doi: 10.1128/jvi.02500-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02500-14</ArticleId><ArticleId IdType="pmc">PMC4300672</ArticleId><ArticleId IdType="pubmed">25355886</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato M, Ohashi J, Tsuchiya N, et al. Association of HLA-A*3303-B*4403-DRB1*1302 haplotype, but not of TNFA promoter and NKp30 polymorphism, with postherpetic neuralgia (PHN) in the Japanese population. Genes Immun. 2002;3:477&#x2013;481. doi: 10.1038/sj.gene.6363890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gene.6363890</ArticleId><ArticleId IdType="pubmed">12486606</ArticleId></ArticleIdList></Reference><Reference><Citation>Naemi FMA, Al-Adwani S, Al-Khatabi H, Al-Nazawi A. Association between the HLA genotype and the severity of COVID-19 infection among South Asians. J Med Virol. 2021;93:4430&#x2013;4437. doi: 10.1002/jmv.27003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27003</ArticleId><ArticleId IdType="pmc">PMC8251353</ArticleId><ArticleId IdType="pubmed">33830530</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente L, Mart&#xed;n MM, Franco A, et al. HLA genetic polymorphisms and prognosis of patients with COVID-19. Med Intensiva (Engl Ed) 2021;45:96&#x2013;103. doi: 10.1016/j.medin.2020.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medin.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7905376</ArticleId><ArticleId IdType="pubmed">32988645</ArticleId></ArticleIdList></Reference><Reference><Citation>Novelli A, Andreani M, Biancolella M, et al. HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients. Hla. 2020;96:610&#x2013;614. doi: 10.1111/tan.14047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.14047</ArticleId><ArticleId IdType="pmc">PMC7461491</ArticleId><ArticleId IdType="pubmed">32827207</ArticleId></ArticleIdList></Reference><Reference><Citation>Thio CL, Thomas DL, Karacki P, et al. Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol. 2003;77:12083&#x2013;12087. doi: 10.1128/jvi.77.22.12083-12087.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.77.22.12083-12087.2003</ArticleId><ArticleId IdType="pmc">PMC254245</ArticleId><ArticleId IdType="pubmed">14581545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksiaa L, Ayed-Jendoubi S, Sfar I, et al. Clearance and persistence of hepatitis C virus in a Tunisian population: association with HLA class I and class II. Viral Immunol. 2007;20:312&#x2013;319. doi: 10.1089/vim.2006.0060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2006.0060</ArticleId><ArticleId IdType="pubmed">17603847</ArticleId></ArticleIdList></Reference><Reference><Citation>Opsteen S, Files JK, Fram T, Erdmann N. The role of immune activation and antigen persistence in acute and long COVID. J Investig Med. 2023;71:545&#x2013;562. doi: 10.1177/10815589231158041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10815589231158041</ArticleId><ArticleId IdType="pmc">PMC9996119</ArticleId><ArticleId IdType="pubmed">36879504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouladseresht H, Ghamar Talepoor A, Farjadian S, Khosropanah S, Doroudchi M. Anti-varicella zoster virus igg and hscrp levels correlate with progression of coronary artery atherosclerosis. Iran J Allergy Asthma Immunol. 2019;18:543&#x2013;53. doi: 10.18502/ijaai.v18i5.1924.</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/ijaai.v18i5.1924</ArticleId><ArticleId IdType="pubmed">32245298</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouladseresht H, Safa A, Khosropanah S, Doroudchi M. Increased frequency of HLA-A*02 in patients with atherosclerosis is associated with VZV seropositivity. Arch Physiol Biochem. 2021;127:351&#x2013;358. doi: 10.1080/13813455.2019.1640253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13813455.2019.1640253</ArticleId><ArticleId IdType="pubmed">31306045</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C, Willscher E, Paschold L, et al. The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. 2022;3:100663. doi: 10.1016/j.xcrm.2022.100663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;224:1839&#x2013;1848. doi: 10.1093/infdis/jiab490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappelmann N, Dantzer R, Khandaker GM. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology. 2021;131:105295. doi: 10.1016/j.psyneuen.2021.105295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2021.105295</ArticleId><ArticleId IdType="pmc">PMC8172271</ArticleId><ArticleId IdType="pubmed">34119855</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, et al. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10:761&#x2013;75. doi: 10.1016/s2213-2600(22)00127-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang M, Wu X, Jing H, Novakovic VA, Shi J. The intersection of obesity and (long) COVID-19: hypoxia, thrombotic inflammation, and vascular endothelial injury. Front Cardiovasc Med. 2023;10:1062491. doi: 10.3389/fcvm.2023.1062491.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2023.1062491</ArticleId><ArticleId IdType="pmc">PMC9941162</ArticleId><ArticleId IdType="pubmed">36824451</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugliese G, Liccardi A, Graziadio C, Barrea L, Muscogiuri G, Colao A. Obesity and infectious diseases: pathophysiology and epidemiology of a double pandemic condition. Int J Obes (Lond) 2022;46:449&#x2013;465. doi: 10.1038/s41366-021-01035-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41366-021-01035-6</ArticleId><ArticleId IdType="pubmed">35058571</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, Mcivor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021;93:1013&#x2013;1022. doi: 10.1002/jmv.26368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Taboada M, Cari&#xf1;ena A, Moreno E, et al. Post-COVID-19 functional status six-months after hospitalization. J Infect. 2021;82:e31&#x2013;e33. doi: 10.1016/j.jinf.2020.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.12.022</ArticleId><ArticleId IdType="pmc">PMC7834022</ArticleId><ArticleId IdType="pubmed">33373650</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B, Cassar MP, Tunnicliffe EM, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. E Clin Med. 2021;31:100683. doi: 10.1016/j.eclinm.2020.100683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100683</ArticleId><ArticleId IdType="pmc">PMC7808914</ArticleId><ArticleId IdType="pubmed">33490928</ArticleId></ArticleIdList></Reference><Reference><Citation>Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, et al. COVID-19 infection: an overview on cytokine storm and related interventions. Virol J. 2022;19:92. doi: 10.1186/s12985-022-01814-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01814-1</ArticleId><ArticleId IdType="pmc">PMC9134144</ArticleId><ArticleId IdType="pubmed">35619180</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang L, Yin Z, Hu Y, Mei H. Controlling cytokine storm is vital in COVID-19. Front Immunol. 2020;11:570993. doi: 10.3389/fimmu.2020.570993.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.570993</ArticleId><ArticleId IdType="pmc">PMC7734084</ArticleId><ArticleId IdType="pubmed">33329533</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6:a016295. doi: 10.1101/cshperspect.a016295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a016295</ArticleId><ArticleId IdType="pmc">PMC4176007</ArticleId><ArticleId IdType="pubmed">25190079</ArticleId></ArticleIdList></Reference><Reference><Citation>Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, Mcdermott M. Tumour necrosis factor signalling in health and disease. F1000Res. 2019;8:17023. doi: 10.12688/f1000research.17023.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.17023.1</ArticleId><ArticleId IdType="pmc">PMC6352924</ArticleId><ArticleId IdType="pubmed">30755793</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi-Pooya AA, Akbari A, Emami A, et al. risk factors associated with long COVID syndrome: a retrospective study. Iran J Med Sci. 2021;46:428&#x2013;36. doi: 10.30476/ijms.2021.92080.2326.</Citation><ArticleIdList><ArticleId IdType="doi">10.30476/ijms.2021.92080.2326</ArticleId><ArticleId IdType="pmc">PMC8611223</ArticleId><ArticleId IdType="pubmed">34840383</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81:e4&#x2013;e6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao YM, Shang YM, Song WB, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. E Clin Med. 2020;25:100463. doi: 10.1016/j.eclinm.2020.100463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100463</ArticleId><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27:89&#x2013;95. doi: 10.1016/j.cmi.2020.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.023</ArticleId><ArticleId IdType="pmc">PMC7510771</ArticleId><ArticleId IdType="pubmed">32979574</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottschalk CG, Peterson D, Armstrong J, Knox K, Roy A. Potential molecular mechanisms of chronic fatigue in long haul COVID and other viral diseases. Infect Agent Cancer. 2023;18:7. doi: 10.1186/s13027-023-00485-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13027-023-00485-z</ArticleId><ArticleId IdType="pmc">PMC9902840</ArticleId><ArticleId IdType="pubmed">36750846</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostami A, Ciric B. Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J Neurol Sci. 2013;333:76&#x2013;87. doi: 10.1016/j.jns.2013.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2013.03.002</ArticleId><ArticleId IdType="pmc">PMC3726569</ArticleId><ArticleId IdType="pubmed">23578791</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil DS, Narkar S, Dahiphale J, Raka V, Choudhari S, Gondhali G. Long COVID symptoms, pathophysiology and possible mechanisms: Still, we are learning! World J Adv Pharmac Med Res. 2023;4:42&#x2013;57. doi: 10.53346/wjapmr.2023.4.1.0019.</Citation><ArticleIdList><ArticleId IdType="doi">10.53346/wjapmr.2023.4.1.0019</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal&#xfa;cio VCA, Menezes DC, Lima PDL, et al. Evaluation of the hematological patterns from up to 985 days of long COVID: a cross-sectional study. Viruses. 2023;15:879. doi: 10.3390/v15040879.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15040879</ArticleId><ArticleId IdType="pmc">PMC10142608</ArticleId><ArticleId IdType="pubmed">37112859</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ, Halim A, Halim M, et al. Inflammatory and vascular biomarkers in post-COVID-19 syndrome: a systematic review and meta-analysis of over 20 biomarkers. Rev Med Virol. 2023;33:e2424. doi: 10.1002/rmv.2424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2424</ArticleId><ArticleId IdType="pubmed">36708022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechuga GC, Morel CM, De-Simone SG. Hematological alterations associated with long COVID-19. Front Physiol. 2023;14:1203472. doi: 10.3389/fphys.2023.1203472.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2023.1203472</ArticleId><ArticleId IdType="pmc">PMC10411895</ArticleId><ArticleId IdType="pubmed">37565145</ArticleId></ArticleIdList></Reference><Reference><Citation>Littera R, Campagna M, Deidda S, et al. Human leukocyte antigen complex and other immunogenetic and clinical factors influence susceptibility or protection to SARS-CoV-2 infection and severity of the disease course. Sardinian Expe Front Immunol. 2020;11:605688. doi: 10.3389/fimmu.2020.605688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.605688</ArticleId><ArticleId IdType="pmc">PMC7746644</ArticleId><ArticleId IdType="pubmed">33343579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedzierska K, Koutsakos M. The ABC of major histocompatibility complexes and t cell receptors in health and disease. Viral Immunol. 2020;33:160&#x2013;178. doi: 10.1089/vim.2019.0184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2019.0184</ArticleId><ArticleId IdType="pmc">PMC7185345</ArticleId><ArticleId IdType="pubmed">32286182</ArticleId></ArticleIdList></Reference><Reference><Citation>Correale P, Mutti L, Pentimalli F, et al. HLA-B*44 and C*01 prevalence correlates with Covid19 spreading across Italy. Int J Mol Sci. 2020;21:5205. doi: 10.3390/ijms21155205.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21155205</ArticleId><ArticleId IdType="pmc">PMC7432860</ArticleId><ArticleId IdType="pubmed">32717807</ArticleId></ArticleIdList></Reference><Reference><Citation>Basir HRG, Majzoobi MM, Ebrahimi S, et al. Susceptibility and severity of COVID-19 are both associated with lower overall viral-peptide binding repertoire of HLA class I molecules. Especially in Younger People Front Immunol. 2022;13:891816. doi: 10.3389/fimmu.2022.891816.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.891816</ArticleId><ArticleId IdType="pmc">PMC9331187</ArticleId><ArticleId IdType="pubmed">35911710</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Zhang W, Zhang J, He J, Zhu F. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019 (COVID-19) Hla. 2020;96:194&#x2013;196. doi: 10.1111/tan.13941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.13941</ArticleId><ArticleId IdType="pmc">PMC7276866</ArticleId><ArticleId IdType="pubmed">32424945</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Huang S, Gao R, et al. Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discov. 2020;6:83. doi: 10.1038/s41421-020-00231-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-00231-4</ArticleId><ArticleId IdType="pmc">PMC7653987</ArticleId><ArticleId IdType="pubmed">33298875</ArticleId></ArticleIdList></Reference><Reference><Citation>Khor SS, Omae Y, Nishida N, et al. HLA-A*11:01:01:01, HLA-C*12:02:02:01-HLA-B*52:01:02:02, age and sex are associated with severity of Japanese COVID-19 with respiratory failure. Front Immunol. 2021;12:658570. doi: 10.3389/fimmu.2021.658570.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.658570</ArticleId><ArticleId IdType="pmc">PMC8100314</ArticleId><ArticleId IdType="pubmed">33968060</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhkhari M, Caidi H, Sadki K. HLA alleles associated with COVID-19 susceptibility and severity in different populations: a systematic review. Egypt J Med Hum Genet. 2023;24:10. doi: 10.1186/s43042-023-00390-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43042-023-00390-5</ArticleId><ArticleId IdType="pmc">PMC9867832</ArticleId><ArticleId IdType="pubmed">36710951</ArticleId></ArticleIdList></Reference><Reference><Citation>Meysman P, Fedorov D, Van Tendeloo V, Ogunjimi B, Laukens K. Immunological evasion of immediate-early varicella zoster virus proteins. Immunogenetics. 2016;68:483&#x2013;486. doi: 10.1007/s00251-016-0911-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00251-016-0911-4</ArticleId><ArticleId IdType="pubmed">27020058</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervina AA, Pogorelyy MV, Kirk AM, et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8(+) T cells. Nat Immunol. 2022;23:781&#x2013;90. doi: 10.1038/s41590-022-01184-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01184-4</ArticleId><ArticleId IdType="pmc">PMC9106845</ArticleId><ArticleId IdType="pubmed">35383307</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Dijssel J, Hagen RR, De Jongh R, et al. Parallel detection of SARS-CoV-2 epitopes reveals dynamic immunodominance profiles of CD8(+) T memory cells in convalescent COVID-19 donors. Clin Transl Immunol. 2022;11:e1423. doi: 10.1002/cti2.1423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1423</ArticleId><ArticleId IdType="pmc">PMC9568370</ArticleId><ArticleId IdType="pubmed">36254196</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>